

References

I-217

1. Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomized study (ROMULUS). *The Lancet Hematology*. 2019;19:2352-3026.
2. Sehn LH, Kamdar M, Herrera AF, et al. Randomized phase 2 trial of Polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. *Journal of Clinical* 2018;36(15):7507.
3. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Polatuzumab vedotin-piiq. 2020.
4. Micromedex®Solutions Compendia. 2020. Polatuzumab vedotin-piiq.
5. Polivy™ (polatuzumab vedotin-piiq) for injection, for intravenous use. Genentech, Inc. South San Francisco, CA. Revised 06/2019.
6. National Comprehensive Cancer Network (NCCN). Polatuzumab vedotin-piiq. NCCN Drugs and Biologics Compendium®. 2020.
7. Hayes, Inc. Hayes Health Prognosis Overview. Polivy (Polatuzumab vedotin-piiq). Lansdale, PA: Hayes, Inc.; June;
8. Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. *Journal of Hematology & Oncology*. 2020;13(1):1-18.
9. Sawalha Y, Maddocks K. Profile of polatuzumab vedotin in the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: a brief report on the emerging clinical data. *OncoTargets & Therapy*. 2020;13:5123-5133.